End-of-day quote
Korea S.E.
18:00:00 2024-06-25 EDT
|
5-day change
|
1st Jan Change
|
28,500
KRW
|
+0.18%
|
|
+0.18%
|
-19.83%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
505,678
|
419,688
|
828,523
|
665,053
|
-
|
Enterprise Value (EV)
2 |
505.7
|
541.3
|
878.8
|
768.8
|
753.6
|
P/E ratio
|
-543
x
|
13.8
x
|
23.3
x
|
9.33
x
|
9.45
x
|
Yield
|
-
|
2.04%
|
1.13%
|
1.27%
|
1.27%
|
Capitalization / Revenue
|
-
|
0.61
x
|
1.1
x
|
0.8
x
|
0.75
x
|
EV / Revenue
|
-
|
0.79
x
|
1.17
x
|
0.93
x
|
0.85
x
|
EV / EBITDA
|
-
|
6.78
x
|
7.15
x
|
6.22
x
|
6.05
x
|
EV / FCF
|
-
|
11.6
x
|
14.7
x
|
154
x
|
53.8
x
|
FCF Yield
|
-
|
8.66%
|
6.81%
|
0.65%
|
1.86%
|
Price to Book
|
-
|
1.83
x
|
3.08
x
|
2.17
x
|
1.81
x
|
Nbr of stocks (in thousands)
|
23,208
|
23,195
|
23,328
|
23,325
|
-
|
Reference price
3 |
21,702
|
17,990
|
35,550
|
28,500
|
28,500
|
Announcement Date
|
3/21/22
|
2/8/23
|
2/5/24
|
-
|
-
|
1KRW in Million2KRW in Billions3KRW Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
684.4
|
750
|
827.5
|
890
|
EBITDA
1 |
-
|
79.8
|
122.9
|
123.6
|
124.6
|
EBIT
1 |
-
|
64.44
|
99.58
|
105.6
|
105.8
|
Operating Margin
|
-
|
9.42%
|
13.28%
|
12.76%
|
11.88%
|
Earnings before Tax (EBT)
1 |
-
|
46.41
|
51.61
|
95
|
91
|
Net income
1 |
-0.9162
|
33.55
|
34.84
|
73.5
|
72.5
|
Net margin
|
-
|
4.9%
|
4.65%
|
8.88%
|
8.15%
|
EPS
2 |
-39.98
|
1,305
|
1,529
|
3,056
|
3,014
|
Free Cash Flow
3 |
-
|
46,851
|
59,871
|
5,000
|
14,000
|
FCF margin
|
-
|
6,846.09%
|
7,982.59%
|
604.25%
|
1,573.09%
|
FCF Conversion (EBITDA)
|
-
|
58,712.94%
|
48,724%
|
4,044.22%
|
11,235.96%
|
FCF Conversion (Net income)
|
-
|
139,647.45%
|
171,832.5%
|
6,802.72%
|
19,310.34%
|
Dividend per Share
2 |
-
|
367.6
|
400.0
|
361.3
|
361.3
|
Announcement Date
|
3/21/22
|
2/8/23
|
2/5/24
|
-
|
-
|
1KRW in Billions2KRW3KRW in Million Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
156.3
|
165
|
169.8
|
193.2
|
173.4
|
185.9
|
184.2
|
205
|
180.6
|
205.2
|
217
|
218
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
13.32
|
9.403
|
11.56
|
30.16
|
20.32
|
20.57
|
26.11
|
33.3
|
26.25
|
25.05
|
26.6
|
30.7
|
Operating Margin
|
8.52%
|
5.7%
|
6.8%
|
15.62%
|
11.72%
|
11.07%
|
14.17%
|
16.24%
|
14.53%
|
12.21%
|
12.26%
|
14.08%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
-
|
-
|
13.08
|
-17.91
|
24.96
|
20.09
|
19.2
|
20.1
|
14.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
7.03%
|
-9.72%
|
12.18%
|
11.12%
|
9.36%
|
9.26%
|
6.47%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/16/22
|
8/16/22
|
11/15/22
|
2/8/23
|
5/15/23
|
8/14/23
|
11/14/23
|
2/5/24
|
5/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
122
|
50.3
|
104
|
88.6
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
1.524
x
|
0.4093
x
|
0.8388
x
|
0.7107
x
|
Free Cash Flow
2 |
-
|
46,851
|
59,871
|
5,000
|
14,000
|
ROE (net income / shareholders' equity)
|
-
|
16.1%
|
14.3%
|
22.2%
|
18.1%
|
ROA (Net income/ Total Assets)
|
-
|
4.73%
|
5.81%
|
9.5%
|
8.5%
|
Assets
1 |
-
|
708.6
|
599.3
|
773.7
|
852.9
|
Book Value Per Share
3 |
-
|
9,813
|
11,542
|
13,153
|
15,724
|
Cash Flow per Share
|
-
|
2,467
|
3,790
|
-
|
-
|
Capex
1 |
-
|
9.91
|
27.3
|
22.9
|
24.5
|
Capex / Sales
|
-
|
1.45%
|
3.64%
|
2.77%
|
2.76%
|
Announcement Date
|
3/21/22
|
2/8/23
|
2/5/24
|
-
|
-
|
1KRW in Billions2KRW in Million3KRW Last Close Price
28,500
KRW Average target price
41,667
KRW Spread / Average Target +46.20% Consensus |
1st Jan change
|
Capi.
|
---|
| -19.83% | 478M | | +54.61% | 811B | | +43.79% | 640B | | -6.33% | 353B | | +20.62% | 333B | | +10.44% | 302B | | +18.00% | 246B | | +2.62% | 225B | | +12.76% | 218B | | +8.61% | 168B |
Other Pharmaceuticals
|